Ionis Pharmaceuticals Presented Positive Results from Two Late Studies of investigational Product Donidalorsen

Ionis Parmaceuticals Treating Hereditary Angioedema
On May 31, 2024, Ionis Pharmaceuticals (IONS) announced positive results from two Phase 3 OASIS-HAE and OASIS plus studies of the firm’s Donidalorsen in patients with hereditary angioedema (HAE).

  • Donidalorsen demonstrating a sustained significant reduction in monthly HAE attack rates and continued attack rate improvement of >90% after one year treatment . . .
    This content is for paid subscribers.
    Please click here to subscribe or here to log in.